Craig-Hallum raised the firm’s price target on Exact Sciences (EXAS) to $85 from $65 and keeps a Buy rating on the shares. The firm would be a buyer of Exact Sciences. With the Freenome deal in place and Shield V2 data out, Craig-Hallum thinks the Street will begin to focus on execution. With a stable of incremental near-term revenue growth drivers, prospects for continued EBITDA margin expansion, substantially improving cash flow, and potential upside to estimates, the stock could break out of this two-year cycle, argues the firm.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences launches Cancerguard test in the U.S.
- Promising Growth Prospects for Exact Sciences: Buy Rating Justified by Strong Cologuard Performance and Strategic Initiatives
- Cathie Wood Buys Deere Stock (DE) on Post-Earnings Dip, Builds Stakes in Exact Sciences and Robinhood Stocks
- Cathie Wood’s ARK Investment buys 298K shares of Exact Sciences today
- Exact Sciences price target lowered to $60 from $65 at BTIG